The North America Anticoccidial Drugs Market size is estimated at USD 537.19 million in 2024, and is expected to reach USD 673.61 million by 2029, growing at a CAGR of 4.63% during the forecast period (2024-2029).
Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.
Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.
Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.
However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.
Furthermore, these drugs are widely used for the prevention of coccidiosis, due to its broad-spectrum activity against the majority of pathogenic species of coccidian and lack of development of drug resistance. Each has a different mode of action and no significant resistance has been developed. These drugs are commonly added to the starter and grower feeds, but not to the finisher or withdrawal feeds.
Furthermore, when the same ionophore anticoccidial is added to the starter and grower feeds, it is known as a straight program. In 2017, the US Food and Drug Administration reported that 82% of all domestic sales and distribution of non-medically important antimicrobials were from ionophores, amounting to 4,394,850 kilo gram.
As a result of the aforementioned factors, the ionophore anticoccidial segment is expected to experience healthy growth during the forecast period.
This product will be delivered within 2 business days.
Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.
Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.
Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.
However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.
North America Anticoccidial Drugs Market Trends
The Ionophore Anticoccidial segment dominates the North America Anticoccidial Drugs Market
A major breakthrough in the prevention of coccidiosis through feed medication occurred in 1972, with the launch of the first polyether ionophore anticoccidial, monensin. This type of anticoccidial agent has been commonly referred to as ionophores, a term derived from their general chemical structure. Ionophores are the fermentation products of Streptomyces and other fungi species.Furthermore, these drugs are widely used for the prevention of coccidiosis, due to its broad-spectrum activity against the majority of pathogenic species of coccidian and lack of development of drug resistance. Each has a different mode of action and no significant resistance has been developed. These drugs are commonly added to the starter and grower feeds, but not to the finisher or withdrawal feeds.
Furthermore, when the same ionophore anticoccidial is added to the starter and grower feeds, it is known as a straight program. In 2017, the US Food and Drug Administration reported that 82% of all domestic sales and distribution of non-medically important antimicrobials were from ionophores, amounting to 4,394,850 kilo gram.
As a result of the aforementioned factors, the ionophore anticoccidial segment is expected to experience healthy growth during the forecast period.
North America Anticoccidial Drugs Industry Overview
The North America Anticoccidial Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Zoetis Animal Healthcare, Phibro Animal Health Corporation, Huvepharma, Elanco, Ceva Animal Health Inc., MSD Animal Health, Vetoquinol SA, Impextraco NV.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Zoetis Animal Healthcare
- Phibro Animal Health Corporation
- Huvepharma
- Elanco
- Ceva Animal Health Inc.
- MSD Animal Health
- Vetoquinol SA
- Impextraco NV
Methodology
LOADING...
